Impact of dialysis dependence on survival for multiple myeloma with renal impairment: a multicenter study in China

被引:0
|
作者
Jian, Yuan [1 ]
Zhou, Huixing [1 ]
Xie, Weiwei [2 ]
Ren, Yuan [3 ]
Zhang, Zhiyao [1 ]
Yang, Guangzhong [1 ]
Geng, Chuanying [1 ]
Jia, Jing [1 ]
Chen, Wenming [1 ]
Huang, Wenrong [3 ]
Cen, Xinan [2 ]
Gao, Wen [1 ]
机构
[1] Capital Med Univ, Beijing Chaoyang Hosp, Myeloma Res Ctr Beijing, Dept Hematol, Beijing, Peoples R China
[2] Peking Univ First Hosp, Dept Hematol, Beijing, Peoples R China
[3] Gen Hosp Peoples Liberat Army, Med Ctr 5, Dept Hematol, Beijing, Peoples R China
来源
AMERICAN JOURNAL OF CANCER RESEARCH | 2023年 / 13卷 / 04期
基金
北京市自然科学基金;
关键词
Multiple myeloma; renal impairment; dialysis dependence; dialysis independence; survival; DIAGNOSIS; RECOVERY; POPULATION; MORTALITY; FAILURE; OUTCOMES; THERAPY;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Renal impairment (RI) is a very common complication of multiple myeloma (MM) with a negative impact on survival. Herein we retrospectively analyzed 334 MM patients with renal impairment at diagnosis from three hospi-tals in China. All 334 patients were divided into three groups, including dialysis dependence (n=43), dialysis inde-pendence (n=42), and without dialysis (n=249). Compared with dialysis independence and without dialysis groups, dialysis dependence group had the lowest overall hematologic response (48.8% vs. 97.6% vs. 77.1%, P<0.001) and overall renal response (0.0% vs. 97.6% vs. 72.7%, P<0.001), as well as the highest early mortality within 24 months (50.0% vs. 24.4% vs. 26.3%, P=0.006). Dialysis dependence group had similar progression-free survival (24 vs. 26 vs. 27 months, P=0.231) and significantly shorter overall survival (25 vs. 69 vs. 45 months, P=0.001). Dialysis dependence was independently associated with high mortality within 24 months and shorter overall survival. In conclusion, MM patients with dialysis dependence still tend to suffer a dismal disease course, including a high probability to suffer early mortality, worse hematological and renal response, as well as shorter survival. Dialysis independence could be very promising for survival improvement.
引用
收藏
页码:1571 / 1581
页数:11
相关论文
共 50 条
  • [31] Impact of the renal failure in multiple myeloma
    Badea, M.
    Badea, D.
    Genuche, A.
    Mitrut, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 213 - 214
  • [32] Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma
    S Ozaki
    H Handa
    T Saitoh
    H Murakami
    M Itagaki
    H Asaoku
    K Suzuki
    A Isoda
    M Matsumoto
    M Sawamura
    J Konishi
    K Sunami
    N Takezako
    S Hagiwara
    Y Kuroda
    T Chou
    E Nagura
    K Shimizu
    Blood Cancer Journal, 2015, 5 : e349 - e349
  • [33] Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma
    Ozaki, S.
    Handa, H.
    Saitoh, T.
    Murakami, H.
    Itagaki, M.
    Asaoku, H.
    Suzuki, K.
    Isoda, A.
    Matsumoto, M.
    Sawamura, M.
    Konishi, J.
    Sunami, K.
    Takezako, N.
    Hagiwara, S.
    Kuroda, Y.
    Chou, T.
    Nagura, E.
    Shimizu, K.
    BLOOD CANCER JOURNAL, 2015, 5 : e349 - e349
  • [34] Renal impairment in multiple myeloma: A single center experience
    Gorsane, Imen
    Barbouch, S.
    Mayara, M.
    Ben Abdelghani, K.
    Goucha, R.
    Ben Hamida, F.
    Hedri, H.
    Ben Abdallah, T.
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2016, 27 (03) : 480 - 485
  • [35] EFFECTS OF BORTEZOMIB ON RENAL IMPAIRMENT MULTIPLE MYELOMA PATIENTS
    Chen, W.
    Lu, J.
    Hou, J.
    HAEMATOLOGICA, 2013, 98 : 340 - 341
  • [36] Renal Impairment in Multiple Myeloma: Time Is of the Essence Reply
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (11) : E314 - E314
  • [37] Optimizing the Treatment of Patients With Multiple Myeloma and Renal Impairment
    Grzasko, Norbert
    Morawska, Marta
    Hus, Marek
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (04): : 187 - 198
  • [38] EVALUATION OF RENAL RESPONSE AND SURVIVAL IN PRE-DIALYSIS PATIENTS WITH MULTIPLE MYELOMA IN TWO DIFFERENT DECADES: A SINGLE CENTRE STUDY
    Ali, Hatem
    Kishore, Bhuvan
    Baharani, Jyoti
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [39] Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study
    Kastritis, Efstathios
    Terpos, Evangelos
    Symeonidis, Argiris
    Labropoulou, Vasiliki
    Delimpasi, Sosana
    Mancuso, Katia
    Zamagni, Elena
    Katodritou, Eirini
    Rivolti, Elena
    Kyrtsonis, Marie-Christine
    Roussou, Maria
    Fotiou, Despina
    Theodorakakou, Foteini
    Ntanasis-Stathopoulos, Ioannis
    Hatjiharissi, Evdoxia
    Kanellias, Nikolaos
    Migkou, Magdalini
    Cheliotis, Giorgos
    Manousou, Kyriaki
    Gavriatopoulou, Maria
    Dimopoulos, Meletios A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (09) : E226 - E229
  • [40] Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma
    Ozaki, Shuji
    Handa, Hiroshi
    Saitoh, Takayuki
    Sunami, Kazutaka
    Ishida, Tadao
    Suzuki, Kenshi
    Narita, Tomoko
    Iida, Shinsuke
    Nakamura, Yuichi
    Suzuki, Kazuhito
    Nishimura, Noriko
    Murakami, Hirokazu
    Shimizu, Kazuyuki
    BLOOD, 2019, 134